Marked, Lasting Disease Regression and Concomitantly Induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in a Patient With Lung Adenocarcinoma and Autoantibodies Receiving Atezolizumab Plus Chemotherapy: A Case Report

Various immune-related adverse events can frequently occur, which may be life-threatening if programmed death 1 or its ligand is blocked. Here, we report a rare case of concomitant autoimmune hemolytic anemia and hemophagocytic lymphohistiocytosis caused by atezolizumab plus chemotherapy in a patien...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Yoshinari Endo, MD, Yusuke Inoue, MD, PhD, Masato Karayama, MD, PhD, Yasuyuki Nagata, MD. PhD, Hironao Hozumi, MD, PhD, Yuzo Suzuki, MD, PhD, Kazuki Furuhashi, MD, PhD, Noriyuki Enomoto, MD, PhD, Tomoyuki Fujisawa, MD, PhD, Yutaro Nakamura, MD, PhD, Naoki Inui, MD, PhD, Takafumi Suda, MD, PhD
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Elsevier 2022-01-01
Serie:	JTO Clinical and Research Reports
Soggetti:	Immune checkpoint inhibitors Lung cancer Autoimmune hemolytic anemia Hemophagocytic lymphohistiocytosis Case report
Accesso online:	http://www.sciencedirect.com/science/article/pii/S2666364321001223
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!